AAN guideline finds diazepam medication is effective for treating children with cerebral palsy A fresh guideline from the American Academy of Neurology and the Child Neurology Society finds botulinum toxin type A to be a highly effective treatment for spasticity, muscle tightness that interferes with movement, in adolescents and children with cerebral palsy, but poses some risk. Spasticity in children with cerebral palsy is most beneficial treated by a multidisciplinary medical and medical team, said lead guideline writer Mauricio R.Provides announced that it has initiated a Stage 2 scientific trial of ARX-02, a proprietary sublingual sufentanil NanoTab item candidate for cancer breakthrough pain control. The primary objective of this multicenter, randomized, placebo-controlled, crossover study is evaluation of safety, efficacy and tolerability of ARX-02 relative to placebo in cancer individuals experiencing episodic breakthrough discomfort. ‘We are very happy to possess initiated the dosing of our initial individual in this proof-of-concept research,’ states AcelRx Chief Executive Officer Thomas Schreck.